<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://pharmoniq.com/news/jnj-to-pay-2-2b-upfront-for-ollin-and-its-phase-3-eye-drug</loc>
    <news:news>
      <news:publication>
        <news:name>PharmoniQ</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:04:39.857Z</news:publication_date>
      <news:title>J&amp;J to Pay $2.2B Upfront for Ollin and Its Phase 3 Eye Drug</news:title>
      <news:keywords>Johnson &amp; Johnson, Ollin Biosciences, Ophthalmology, Acquisitions, Blackstone</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pharmoniq.com/news/pfizer-starna-in-vivo-car-t-licensing-deal-330m-upfront</loc>
    <news:news>
      <news:publication>
        <news:name>PharmoniQ</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T08:11:15.112Z</news:publication_date>
      <news:title>Pfizer to Pay $330M Upfront to Enter In Vivo CAR-T With Starna</news:title>
      <news:keywords>Pfizer, Starna Therapeutics, in vivo CAR-T, licensing, autoimmune disease</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pharmoniq.com/news/sellas-gps-vaccine-phase-3-regal-aml-survival</loc>
    <news:news>
      <news:publication>
        <news:name>PharmoniQ</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T07:58:08.101Z</news:publication_date>
      <news:title>SELLAS Vaccine Cuts Death Risk 41% in Phase 3 Leukemia Trial</news:title>
      <news:keywords>SELLAS Life Sciences, acute myeloid leukemia, cancer vaccine, phase 3, clinical trials</news:keywords>
    </news:news>
  </url>
</urlset>